1-3 of 3
Arnalda Lanfranchi, PhD
Close
Sort by
Journal Articles

Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia

Ilaria Stefania Pagani, PhD, Orietta Spinelli, PhD, Cristina Pirrone, Diana Pigni, Sara Lupoli, PhD, Francesca D'Avila, PhD, Matteo Barcella, Chiara Boroni, Tamara Intermesoli, Ursula Giussani, Federica Bolda, Francesco Pasquali, MD, Francesco Lo Curto, PhD, Arnalda Lanfranchi, PhD, Fulvio Porta, MD, Cristina Barlassina, PhD, Alessandro Rambaldi, MD, Giovanni Porta, MD
Journal: Blood
Blood (2013) 122 (21): 1316.
https://doi.org/10.1182/blood.V122.21.1316.1316
Published: 2013
Journal Articles

Chronic Myeloid Leukemia: Molecular Monitoring of Residual Disease by Genomic DNA Compared to Conventional mRNA Analysis in Follow-Ups up to 8 Years

Ilaria Stefania Pagani, PhD, Orietta Spinelli, PhD, Adelaide Bussini, PhD, Tamara Intermesoli, Francesco Pasquali, MD, Francesco Lo Curto, PhD, Arnalda Lanfranchi, PhD, Fulvio Porta, MD, Alessandro Rambaldi, Giovanni Porta, MD
Journal: Blood
Blood (2011) 118 (21): 1687.
https://doi.org/10.1182/blood.V118.21.1687.1687
Published: 2011
Journal Articles

Ann Arbor Stage Is the Most Important Predictor of Survival for Refractory and Relapsed HIV-Associated Lymphoma Enrolled in a Program of High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation.

Alessandro Re, MD, Chiara Cattaneo, MD, MariaGrazia Michieli, MD, Salvatore Casari, MD, Michele Spina, MD, Maurizio Rupolo, MD, Bernardino Allione, MD, Piero Ferremi, MD, Arnalda Lanfranchi, PhD, Mauro Mazzuccato, MD, Gianpiero Carosi, MD, Umberto Tirelli, MD, Giuseppe Rossi, MD
Journal: Blood
Blood (2004) 104 (11): 893.
https://doi.org/10.1182/blood.V104.11.893.893
Published: 2004